Akebia Therapeutics (AKBA) Non-Current Deffered Revenue (2013 - 2024)

Akebia Therapeutics (AKBA) has 11 years of Non-Current Deffered Revenue data on file, last reported at $43.3 million in Q1 2024.

• Non-Current Deffered Revenue for Q1 2024 came in at $43.3 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2024 was $43.3 million (changed 0.0% YoY), and the FY2023 annual result was $43.3 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue held at $43.3 million in Q1 2024 per AKBA's latest filing, from $43.3 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $65.4 million in Q1 2022 and troughed at $16.6 million in Q2 2021.
• A 5-year average of $37.3 million and a median of $43.3 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2021 and 2022: Non-Current Deffered Revenue slumped 54.91% in 2021, then jumped 238.65% in 2022.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $25.3 million in 2020, then fell by 15.27% to $21.5 million in 2021, then soared by 101.62% to $43.3 million in 2022, then changed by 0.0% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024.
• Business Quant data shows AKBA's Non-Current Deffered Revenue at $43.3 million in Q1 2024, $43.3 million in Q4 2023, and $43.3 million in Q3 2023.